Item 2.02 Results of Operations and Financial Condition

As discussed below, in connection with participation in the 40th Annual J.P. Morgan Healthcare Conference, Aprea Therapeutics, Inc. (the 'Company") updated its corporate presentation to include disclosure that the Company expects cash and cash equivalents of $50.0 million to $55.0 million (unaudited) as of December 31, 2021.

Because the Company's consolidated financial statements for the year ended December 31, 2021 have not yet been finalized or audited, the preliminary statement of the Company's cash and cash equivalents as of December 31, 2021 in this Item 2.02 is subject to change, and the Company's actual cash and cash equivalents as of December 31, 2021 may differ materially from this preliminary estimate. Accordingly, you should not place undue reliance on this preliminary estimate.

Item 7.01 Regulation FD Disclosure

Beginning on January 13, 2022, the Company will participate in the 40th Annual J.P. Morgan Healthcare Conference. The Company has updated its corporate presentation that it intends to use in connection with its presentation on Thursday January 13, 2022 at 11:15 p.m. Eastern Time in meetings with investors.

A copy of the Company's corporate presentation is attached hereto as Exhibit 99.1 and is hereby incorporated by reference herein.

The information contained in Item 2.02 and Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished pursuant to Item 2.02 and Item 7.01 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly stated by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d)     Exhibits.



Exhibit
Number                                  Description
  99.1       Aprea Therapeutics, Inc. Presentation

  104      The cover page from this Current Report on Form 8-K, formatted as
           Inline XBRL

© Edgar Online, source Glimpses